U.S. Markets closed

The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data

Shanthi Rexaline

The following is a roundup of top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks that hit 52-week highs on Feb. 21.)

  • Eli Lilly And Co (NYSE: LLY)
  • Gossamer Bio Inc (NASDAQ: GOSS): IPO-ed on Feb. 8.
  • Immune Design Corp (NASDAQ: IMDZ): announced a deal to be acquired by Merck & Co., Inc. (NYSE: MRK).
  • Intec Pharma Ltd (NASDAQ: NTEC)
  • Omnicell, Inc. (NASDAQ: OMCL)
  • PDL BioPharma Inc (NASDAQ: PDLI)

Down In The Dumps

(Biotech stocks that hit 52-week lows on Feb. 21.)

  • Endologix, Inc. (NASDAQ: ELGX)
  • Innovate Biopharmaceuticals Inc (NASDAQ: INNT)
  • Seelos Therapeutics Inc (NASDAQ: SEEL)

Stock In Focus Earnings

BioTelemetry Inc (NASDAQ: BEAT) reported fourth-quarter revenues of $103.6 million, up 12.9 percent year-over-year, and adjusted earnings per share of 56 cents compared to the year-ago's 32 cents.

Analysts expected EPS of 43 cents per share on revenues of $102.84 million.

The stock fell 4.99 percent to $69.68 in after-hours trading.

bluebird bio Inc (NASDAQ: BLUE)'s fourth quarter revenues climbed from $4.2 million to $19.2 million. The company's net loss widened from $2.52 to $2.72. Analysts expected a wider loss of $2.86 per share on revenues of $8.12 million.

The stock rose 2.17 percent to $130 in after-hours trading.

TherapeuticsMD Inc (NASDAQ: TXMD) said its fourth-quarter revenues increased from $4.1 million to $5.1 million. The net loss per share widened from 10 cents to 17 cents. The results matched analysts' expectation.

The stock rallied 3.93 percent to $5.29 in after-hours trading.

View more earnings on XBI

See also: Intercept Shares Soar To Multimonth High After NASH Drug Aces Late-Stage Trial

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)'s 2018 fourth-quarter revenues of $353.2 million compared to $358.3 million in the year-ago period. The GAAP net loss narrowed from 30 cents per share to 3 cents per share.

On a non-GAAP basis, the company reversed to a loss of $10.8 million from a profit of $5.2 million.

For 2019, the company guided to revenue of $1.68 billion to $1.75 billion, while the consensus estimate calls for revenue of $1.73 billion.

The stock fell 5.98 percent to $83.50 in after-hours trading.

Moleculin Biotech Inc (NASDAQ: MBRX) reported a loss of 46 cents per share for 2018 compared to 53 cents per share for 2017. Analysts had expected a loss of 47 cents per share.

The stock slipped 4.11 percent to $1.31 in after-hours trading.

On The Radar Clinical Trial Results

  • Orchard Therapeutics PLC – ADR (NASDAQ: ORTX) is due to present Phase 1/2 data for its OTL-101, being evaluated for adenosine deaminase severe combined immunodeficiency at 10:30 a.m. ET. 


  • Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) (before the market open)
  • Insmed Incorporated (NASDAQ: INSM)

Related Link: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

See more from Benzinga

© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.